A systematic review of atypical antipsychotic drugs in schizophrenia.

Authors' objectives The main objectives were to assess the clinical effectiveness, safety and cost-effectiveness of 'atypical' antipsychotic drugs in schizophrenia in comparison with conventional antipsychotic drugs, placebo and other atypical antipsychotic drugs. The secondary objectives of the review were to investigate response in those with treatment-resistant schizophrenia, with predominantly negative symptoms or experiencing their first episode of schizophrenia.

[1]  J. Gorman,et al.  Efficacy of a 12 week trial of olanzapine in treatment refractory schizophrenia or schizoaffective disorder , 1998, Schizophrenia Research.

[2]  P. Weiden,et al.  Switching from conventional antipsychotics to ziprasidone: An interim analysis of a 6-week study , 1999, European Neuropsychopharmacology.

[3]  P. Sanders,et al.  Cardiovascular Adverse Effects of Antipsychotic Drugs , 2000, Drug safety.

[4]  W. Rein,et al.  Long‐term safety and efficacy of amisulpride in subchronic or chronic schizophrenia , 2000 .

[5]  T. Manschreck,et al.  Clozapine in the back wards. , 1994, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[6]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[7]  H. Knegtering,et al.  Sexual dysfunction and prolactin levels in patients using risperidone or olanzapine , 2000, Schizophrenia Research.

[8]  M. Brecher,et al.  The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia , 2000, International journal of psychiatry in clinical practice.

[9]  Abraham Weizman,et al.  Myotoxicity and Neurotoxicity during Clozapine Treatment , 2000, Clinical neuropharmacology.

[10]  D. Naber,et al.  Clinical Management of Clozapine Patients in Relation to Efficacy and Side-Effects , 1992, British Journal of Psychiatry.

[11]  David Taylor,et al.  Refractory schizophrenia and atypical antipsychotics , 2000, Journal of psychopharmacology.

[12]  Péré Jj.  [Clinical psychopharmacology: the example of clozapine (Leponex)]. , 1995 .

[13]  W. Fleischhacker,et al.  Clozapine-induced transient white blood count disorders. , 1994, The Journal of clinical psychiatry.

[14]  L. Alphs,et al.  Clozapine and sudden death , 2000, The Lancet.

[15]  Y M Bai,et al.  A retrospective study of clozapine and urinary incontinence in Chinese in‐patients , 1999, Acta psychiatrica Scandinavica.

[16]  C. Beasley,et al.  Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial , 1997, European Neuropsychopharmacology.

[17]  P. Haddad,et al.  Differing tolerability profiles among atypical antipsychotics. , 2001, The American journal of psychiatry.

[18]  M. Brecher,et al.  Weight gain with risperidone. , 1997, Journal of clinical psychopharmacology.

[19]  S. Ayis,et al.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients , 2000, The Lancet.

[20]  S. Strakowski,et al.  Attentional improvement following quetiapine fumarate treatment in schizophrenia. , 1998, Schizophrenia research.

[21]  L. Lindström.  The effect of long‐term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years , 1988, Acta psychiatrica Scandinavica.

[22]  K. Meehan,et al.  Change in extrapyramidal symptoms with olanzapine in comparison with other antipsychotic agents , 2000, Schizophrenia Research.

[23]  A. Lesmes,et al.  [Myasthenic syndrome induced by clozapine]. , 1990, Revista clinica espanola.

[24]  P. Preterre.  [Blood clozapine level and therapeutic adjustment]. , 1995, L'Encephale.

[25]  R. Emsley,et al.  Efficacy of seroquel in treating all of the positive and negative symptoms of schizophrenia , 2000, Schizophrenia Research.

[26]  Daniel R. Wilson,et al.  New-onset diabetes and ketoacidosis with atypical antipsychotics , 2003, Schizophrenia Research.

[27]  R. Ganguli,et al.  Weight gain associated with antipsychotic drugs. , 1999, The Journal of clinical psychiatry.

[28]  M. Knapp.  Measuring the economic benefit of treatment with atypical antipsychotics , 1998, European Psychiatry.

[29]  P. Czobor,et al.  Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. , 1998, The Journal of clinical psychiatry.

[30]  R. Rosenheck,et al.  Clozapine and suicide. , 1999, Psychiatric services.

[31]  C. Lançon,et al.  [Psychoses, mood, suicidal tendencies and clozapine]. , 1997, L'Encephale.

[32]  K. Huybrechts,et al.  Risperidone: An assessment of its economic benefits in the treatment of schizophrenia , 1998 .

[33]  D. Javitt,et al.  A naturalistic outcome study of risperidone treatment among hospital patients. , 1996, Psychiatric services.

[34]  H. Möller,et al.  Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. , 2000, Journal of Clinical Psychiatry.

[35]  Abraham Weizman,et al.  The effect of long-term antipsychotic treatment on the body weight of patients suffering from chronic schizophrenia: clozapine versus classical antipsychotic agents. , 1999, International clinical psychopharmacology.

[36]  M. Tohen,et al.  Olanzapine in the treatment of mania: A placebo-controlled four-week study , 1999, European Neuropsychopharmacology.

[37]  K. Wahlbeck,et al.  Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis. , 1999, International journal of psychiatry in clinical practice.

[38]  C. Epstein,et al.  Clozapine-induced EEG abnormalities and clinical response to clozapine. , 1995, The Journal of neuropsychiatry and clinical neurosciences.

[39]  R. Herman,et al.  Drug interactions and the statins. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[40]  P. Masand,et al.  298. Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders , 2000, Biological Psychiatry.

[41]  Yang Js.  An analysis of 106 cases of schizophrenia treated with clozapine , 1984 .

[42]  J. Švestka,et al.  [Clinical experience with clozapin (author's transl)]. , 1975, Ceskoslovenska psychiatrie.

[43]  S. Reid.  Suicide in schizophrenia. A review of the literature. , 1998, Journal of mental health.

[44]  J. Kane.  [Clozapine in the treatment of schizophrenia]. , 1991, L'Encephale.

[45]  Roopali Sharma,et al.  Risperidone-Induced Neuroleptic Malignant Syndrome , 1996, The Annals of pharmacotherapy.

[46]  W. Günther,et al.  EEG Alterations and Seizures during Treatment with Clozapine , 1993, Pharmacopsychiatry.

[47]  D. Taylor,et al.  Atypical antipsychotics and weightgain — a systematic review , 2000, Acta psychiatrica Scandinavica.

[48]  M. De Hert,et al.  Health care expenditure on schizophrenia patients in Belgium. , 1999, Schizophrenia bulletin.

[49]  G. Remington,et al.  The Canadian experience with risperidone for the treatment of schizophrenia: an overview. , 1998, Journal of psychiatry & neuroscience : JPN.

[50]  M. Fuller,et al.  Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. , 1996, The Journal of clinical psychiatry.

[51]  R. Rosenheck,et al.  How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. , 1999, Schizophrenia bulletin.

[52]  P. Krupp,et al.  Clozapine-Associated Agranulocytosis: Risk and Aetiology , 1992, British Journal of Psychiatry.

[53]  M. Launer.  Diarrhoea during treatment with clozapine. , 1992, BMJ.

[54]  Y. Raoul,et al.  [Quality of life of schizophrenic patients and clozapine]. , 1997, L'Encephale.

[55]  M. Mazurek,et al.  Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone , 1999, Neurology.

[56]  G. Tollefson,et al.  Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses , 1998, British Journal of Psychiatry.

[57]  D. Revicki,et al.  A cost-effectiveness clinical decision analysis model for schizophrenia. , 1998, The American journal of managed care.

[58]  Del D. Miller,et al.  Review and management of clozapine side effects. , 2000, The Journal of clinical psychiatry.

[59]  S. Pacia,et al.  Seizures during clozapine therapy. , 1994, The Journal of clinical psychiatry.

[60]  Craig W. Reynolds,et al.  The safety and efficacy of zotepine in the treatment of schizophrenia: Results of a one-year naturalistic clinical trial , 2000, International journal of psychiatry in clinical practice.

[61]  F. Mazzeo,et al.  [Intensive hospital monitoring of adverse reactions to benzodiazepines and neuroleptic agents]. , 1998, Minerva medica.

[62]  S. Kasper,et al.  How much do novel antipsychotics benefit the patients? , 1998, International clinical psychopharmacology.

[63]  D. Bilsker.  Cost-benefits of risperidone. , 1996, Psychiatric services.

[64]  C. Beasley,et al.  Cardiac safety profile of olanzapine based on preclinical and clinical ECG data , 1999, European Neuropsychopharmacology.

[65]  H. Möller.  Atypical neuroleptics: a new approach in the treatment of negative symptoms , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[66]  C. Galletly,et al.  Relationships between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine , 1997, Psychiatry Research.

[67]  M. Weller,et al.  Does clozapine cause neuroleptic malignant syndrome? , 1993, The Journal of clinical psychiatry.

[68]  B. Kinon,et al.  Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone , 2000, Schizophrenia Research.

[69]  B. Kinon,et al.  Effect of chronic olanzapine treatment on the course of presumptive tardive dyskinesia , 1999, European Neuropsychopharmacology.

[70]  A. Malhotra,et al.  Spectrum of EEG abnormalities during clozapine treatment. , 1994, Electroencephalography and Clinical Neurophysiology.

[71]  D. Zimbroff.  Switching patients from clozapine to risperidone therapy. , 1995, The American journal of psychiatry.

[72]  Richard Horton,et al.  Pardonable revisions and protocol reviews , 1997, The Lancet.

[73]  E. Szabadi.  Clozapine-induced hypersalivation , 1997, British Journal of Psychiatry.

[74]  S. Steingard,et al.  Emergence of obsessive compulsive symptoms during treatment with clozapine. , 1992, The Journal of clinical psychiatry.

[75]  L. Hankoff.  Associate Editor’s Editorial: Laziness, Criminality, and Schizophrenia , 2000 .

[76]  J. Lieberman,et al.  Clozapine and akathisia , 1992, Biological Psychiatry.

[77]  M. Berk,et al.  A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. , 1999, International clinical psychopharmacology.

[78]  M. Dernovsek,et al.  Risperidone is effective in patients with treatment-resistant schizophrenia , 2000, European Neuropsychopharmacology.

[79]  J. Vandenbroucke,et al.  Antipsychotic drugs and venous thromboembolism , 2000, The Lancet.

[80]  Steve Brown.  Excess mortality of schizophrenia , 1997, British Journal of Psychiatry.

[81]  R. Conley,et al.  Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. , 1998, Journal of child and adolescent psychopharmacology.

[82]  E. Coccaro,et al.  An open trial of sertraline in personality disordered patients with impulsive aggression. , 1994, The Journal of clinical psychiatry.

[83]  H. Remschmidt,et al.  [Results of treatment with clozapine in schizophrenic adolescents]. , 1986, Zeitschrift fur Kinder- und Jugendpsychiatrie.

[84]  T. E. Hansen,et al.  Neuroleptic intolerance : Clinical challenges in the psychopharmacology of schizophrenia , 1997 .

[85]  M. Jarema,et al.  Quality of life of schizophrenic patients treated with classic and “old” atypical neuroleptics , 1999, European Neuropsychopharmacology.

[86]  A. Kirkegaard,et al.  Evaluation of side effects due to clozapine in long-term treatment of psychosis. , 1982, Arzneimittel-Forschung.

[87]  J. McKellar,et al.  ‘seroquel’®: An effective atypical antipsychotic with no greater EPS than placebo across the full dose range , 1998, Schizophrenia Research.

[88]  R. Shelton,et al.  The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features , 2000, Schizophrenia Research.

[89]  N. Nair,et al.  Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. , 1998, Journal of clinical psychopharmacology.

[90]  R. Landgraf,et al.  Clozapine and sudden death , 2000, The Lancet.

[91]  S. Aronson.  Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. , 1997, Clinical therapeutics.

[92]  R. Baker,et al.  Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. , 1995, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[93]  T. Barnes,et al.  Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics* , 1999, British Journal of Psychiatry.

[94]  J. Lieberman,et al.  Akathisia and clozapine treatment. , 1993 .

[95]  V. Mastey,et al.  Average dose and weight: Olanzapine vs. risperidone , 1999, European Neuropsychopharmacology.

[96]  S. McGurk.  The effects of clozapine on cognitive functioning in schizophrenia. , 1999, The Journal of clinical psychiatry.

[97]  C. Kozma,et al.  Risperidone, Haloperidol and Clozapine in the South Carolina Medicaid Program , 2001 .

[98]  A. Wood.  Clinical experience with olanzapine, a new atypical antipsychotic , 1998 .

[99]  P. Stránský,et al.  [Long-term clozapine treatment of schizophrenic type psychoses and the significance of side-effects (author's transl)]. , 1977, Ceskoslovenska psychiatrie.

[100]  E. Eşel,et al.  Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients , 2000, European Neuropsychopharmacology.

[101]  H. Demb,et al.  Movement disorders in children with developmental disabilities taking risperidone. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[102]  D. Tarsy.  Movement disorders with neuroleptic drug treatment. , 1984, The Psychiatric clinics of North America.

[103]  T. Terao,et al.  Comparison of Risperidone and Mosapramine Addition to Neuroleptic Treatment in Chronic Schizophrenia , 1999, Neuropsychobiology.

[104]  S. Brook.  A pilot study of intramuscular ziprasidone in the short‐term treatment of patients with acute exacerbation of schizophrenia , 2000, Human psychopharmacology.

[105]  P. Sachdev,et al.  Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. , 1995, Journal of clinical psychopharmacology.

[106]  D. Cicchetti,et al.  Risperidone-associated weight gain in children and adolescents: a retrospective chart review. , 2000, Journal of child and adolescent psychopharmacology.

[107]  J. More.  Seizure with low doses of clozapine. , 1992, The American journal of psychiatry.

[108]  S. Caroff,et al.  Atypical Antipsychotics and Neuroleptic Malignant Syndrome , 2000 .

[109]  J. Raniwalla,et al.  Maintenance of long-term efficacy with ‘seroquel’ , 2000, Schizophrenia Research.

[110]  R. Conigliaro,et al.  Neuroleptic Malignant Syndrome with Risperidone , 1997, Pharmacotherapy.

[111]  I. Palva.  [Hematological complications caused by clozapine (Leponex)]. , 1976, Duodecim; laaketieteellinen aikakauskirja.

[112]  S. Dursun,et al.  Clozapine and sudden death , 2000, The Lancet.

[113]  T. Sharma,et al.  Change in negative symptoms with risperidone predicts improved quality of life in schizophrenia , 2000, Schizophrenia Research.

[114]  N. Schooler,et al.  Ziprasidone's effect on anxiety in a group of outpatients with stable schizophrenia , 2000, European Neuropsychopharmacology.

[115]  A. Stoudemire,et al.  Aetiology and Treatment of Neuroleptic Malignant Syndrome , 1987, Medical toxicology.

[116]  E. Rüther,et al.  Myocarditis Associated with Clozapine Treatment , 2000 .

[117]  A. Kirkegaard,et al.  [Studies on side-effects in treatment of psychoses with clozapine (Leponex)]. , 1977, Ugeskrift for laeger.

[118]  N. Andreasen,et al.  A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. , 1999, The Journal of clinical psychiatry.

[119]  J. Warner.  Evidence-based psychopharmacology 2. Appraising a systematic review: is risperidone better than conventional antipsychotics in the treatment of schizophrenia? , 1999, Journal of psychopharmacology.

[120]  Shepski Jc,et al.  Development and implementation of drug use evaluation (DUE) criteria for risperidone in an outpatient psychiatric setting. , 1996 .

[121]  A. Wehnert.  The European Post‐marketing Observational Serdolect® (EPOS) project: increasing our understanding of schizophrenia therapy , 1998, International clinical psychopharmacology.

[122]  F. Frankenburg,et al.  Cardiorespiratory problems with clozapine. , 1996, The Journal of clinical psychiatry.

[123]  G. Simpson,et al.  Dystonia while changing from clozapine to risperidone. , 1996, Journal of clinical psychopharmacology.

[124]  S. Shima,et al.  A prospective study of tardive dyskinesia in Japan , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[125]  L. Mynors-Wallis,et al.  Outcome of clozapine treatment for patients with treatment-resistant schizophrenia in a local clinical service , 2000 .

[126]  W. Rein,et al.  Social adaptation in schizophrenic patients: Experience with amisulpride , 1999, European Neuropsychopharmacology.

[127]  I. Jalenques.  [Pharmacologic approach to negative symptoms in schizophrenia]. , 1995, L'Encephale.

[128]  M. Olfson,et al.  The Cost of Relapse in Schizophrenia , 2017, PharmacoEconomics.

[129]  J. Aubry,et al.  Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. , 2000, The Journal of clinical psychiatry.

[130]  S. Ulrich,et al.  Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. , 1999, International clinical psychopharmacology.

[131]  B. Küchenhoff.  [The most important side effects of clozapine (Leponex) and their treatment]. , 1993, Psychiatrische Praxis.

[132]  G. Tollefson,et al.  A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo , 1998, European Neuropsychopharmacology.

[133]  C. Halldin,et al.  Implications of brain imaging for the management of schizophrenia , 1998, International clinical psychopharmacology.

[134]  B. Cohen,et al.  Prevalence and severity of akathisia in patients on clozapine , 1991, Biological Psychiatry.

[135]  D. Levinson,et al.  Treatment of schizoaffective disorder and schizophrenia with mood symptoms. , 1999, The American journal of psychiatry.

[136]  D. Jeste,et al.  Lower Incidence of Tardive Dyskinesia with Risperidone Compared with Haloperidol in Older Patients , 1999, Journal of the American Geriatrics Society.

[137]  S. Heimann.  High-dose olanzapine in an adolescent. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[138]  G. Tollefson,et al.  Review of recent clinical studies with olanzapine , 1999, British Journal of Psychiatry.

[139]  J. Zito.  Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. , 1998, The Psychiatric clinics of North America.

[140]  G. Trudel,et al.  The Influence of Schizophrenia and Standard or Atypical Neuroleptics on Sexual and Sociosexual Functioning: A Review , 2000 .

[141]  S. Kasper,et al.  Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates. , 1998, Journal of clinical psychopharmacology.

[142]  W. Glazer.  Depot fluphenazine: risk/benefit ratio. , 1984, The Journal of clinical psychiatry.

[143]  P. Benfield,et al.  A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Schizophrenia , 1996 .

[144]  C. Alderman,et al.  A Two-Year Review of Risperidone Usage on an Acute-Care, Adult Psychiatric Unit , 1997 .

[145]  W. Wilson,et al.  Seizures associated with clozapine treatment in a state hospital. , 1994, The Journal of clinical psychiatry.

[146]  R. Norman,et al.  A comparison of long term outcome in first episode schizophrenia patients treated with risperidone or typical antipsychotics , 1999, European Neuropsychopharmacology.

[147]  G. Tollefson,et al.  Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol , 1998, European Neuropsychopharmacology.

[148]  H. Lamb,et al.  Quetiapine : A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease , 2000 .

[149]  M. Gitlin.  Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. , 1994, The Journal of clinical psychiatry.

[150]  P. Keck,et al.  Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. , 1986, The American journal of psychiatry.

[151]  G. Christodoulou,et al.  Olanzapine-induced neuroleptic malignant syndrome , 2000, European Neuropsychopharmacology.

[152]  K. Reeves,et al.  A comparison of rapid-acting intramuscular (IM) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation , 1998, European Psychiatry.

[153]  J. Lieberman,et al.  Clinical profile of clozapine: Adverse reactions and agranulocytosis , 2005, Psychiatric Quarterly.

[154]  J. Zajecka,et al.  Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. , 2001, The Journal of clinical psychiatry.

[155]  Gram Lf.  Drug information. Bone marrow depression in treatment with clozapine (Leponex) , 1976 .

[156]  L. Lindström,et al.  Long‐term clinical and Social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs , 1994, Acta psychiatrica Scandinavica. Supplementum.

[157]  S. Khoshbin,et al.  Clozapine-Induced Seizures and EEG Abnormalities in Ambulatory Psychiatric Patients , 1998, The Annals of pharmacotherapy.

[158]  G. Currier,et al.  Risperidone oral solution versus intramuscular haloperidol for control of psychotic agitation , 2000, Schizophrenia Research.

[159]  Adityanjee.  Clozapine in patients with NMS , 1991, British Journal of Psychiatry.

[160]  A. Kalali,et al.  Long term treatment with ‘seroquel’: Results of a multinational study of patient satisfaction and acceptability , 1998, Schizophrenia Research.

[161]  J. Peuskens,et al.  Effects of risperidone on affective symptoms in patients with schizophrenia. , 2000 .

[162]  D. Casey.  Clozapine: neuroleptic-induced EPS and tardive dyskinesia , 2004, Psychopharmacology.

[163]  E. Stip,et al.  Quetiapine: are we overreacting in our concern about cataracts (the beagle effect)? , 1999, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[164]  K. Marlowe.  Thrombocytosis due to clozapine treatment: working towards an early marker for clozapine-induced agranulocytosis. , 2000, The British journal of psychiatry : the journal of mental science.

[165]  J. Karagianis,et al.  Clozapine-Associated Neuroleptic Malignant Syndrome: Two New Cases and a Review of the Literature , 1999, The Annals of pharmacotherapy.

[166]  R. Bland,et al.  Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study* , 1991, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[167]  R. Rosenheck,et al.  Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 2000, The Journal of clinical psychiatry.

[168]  P. Young,et al.  The use of atypical antipsychotics in the management of schizophrenia. , 1999, British journal of clinical pharmacology.

[169]  M. Tueth.  Side effects of clozipine (Clozaril) requiring emergency treatment. , 1993, The American journal of emergency medicine.

[170]  D. Kohen,et al.  Atypical antipsychotics and neuroleptic malignant syndrome , 1999, British Journal of Psychiatry.

[171]  C. Adams,et al.  Influence of methodology on outcomes of randomised clozapine trials. , 2000, Pharmacopsychiatry.

[172]  S. Yamawaki,et al.  Trial of treatment with risperidone on outpatients with schizophrenia: a comparison with haloperidol , 1999 .

[173]  S. Roth,et al.  Neuroleptic malignant syndrome: review and analysis of 115 cases , 1987, Biological Psychiatry.

[174]  E. Chow,et al.  Clinical use of clozapine in a major urban setting: one year experience. , 1995, Journal of psychiatry & neuroscience : JPN.

[175]  P. Buckley.  How effective are the second generation antipsychotics , 1998 .

[176]  S. Taylor,et al.  The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia , 1999, Schizophrenia Research.

[177]  J. Mauskopf,et al.  Annual health outcomes and treatment costs for schizophrenia populations. , 1999, The Journal of clinical psychiatry.

[178]  K. Trezise.  ECT with clozapine: efficacy and safety , 1996, British Journal of Psychiatry.

[179]  Philip D. Harvey,et al.  Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychotics , 2000, European Neuropsychopharmacology.

[180]  G. Ramaekers,et al.  [Diabetes mellitus after treatment with clozapine]. , 2000, Nederlands tijdschrift voor geneeskunde.

[181]  É. Albuisson,et al.  [Weight gain and clozapine]. , 1996, L'Encephale.

[182]  E. McCrudden,et al.  Possible Myocarditis with Clozapine , 2000 .

[183]  M. Olkinuora,et al.  Agranulocytosis during treatment with clozapine , 1977, European Journal of Clinical Pharmacology.

[184]  W. Fleischhacker,et al.  Weight gain induced by clozapine , 1995, European Neuropsychopharmacology.

[185]  A. Antal,et al.  The atypical antipsychotic olanzapine does not induce Parkinson-like visuo-perceptual deficits , 1999, European Neuropsychopharmacology.

[186]  J. Kane,et al.  Controlled, Double-blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo , 1999 .

[187]  Haberfellner Em.  Remission of tardive dyskinesia after changing from flupenthixol to olanzapine. , 2000 .

[188]  W. Shen,et al.  QTc prolongation associated with sulpiride and haloperidol use: A pilot crossover-design study , 2000, European Neuropsychopharmacology.

[189]  M. Brecher,et al.  A combined analysis of double‐blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms , 1999, Acta psychiatrica Scandinavica.

[190]  J. Bloom.  Associate Editor's Editorial , 1988 .

[191]  W. Reid.  The treatment of psychosis: resetting the drug cost 'thermostat'. , 1994, The Journal of clinical psychiatry.

[192]  J. Singer.  Clozapine and tardive dyskinesia. , 1983, Archives of general psychiatry.

[193]  D M Steinwachs,et al.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. , 1998, Schizophrenia bulletin.

[194]  J J Bartko,et al.  Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. , 1999, The American journal of psychiatry.

[195]  T. Pollmächer,et al.  Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. , 1999, Journal of clinical psychopharmacology.

[196]  A. Fuchs.  Clozapine: benefits and risks. , 1994, Schizophrenia bulletin.

[197]  J. Lindenmayer.  Treatment Refractory Schizophrenia , 2004, Psychiatric Quarterly.

[198]  R. Leadbetter,et al.  Clozapine-induced weight gain: prevalence and clinical relevance. , 1992, The American journal of psychiatry.

[199]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[200]  B. Green.  Focus on Risperidone , 2000, Current medical research and opinion.

[201]  A. Bulbena,et al.  Drug-induced tardive dyskinesia and mortality: An eight-year follow-up of 36 cases and 36 matched controls , 1998, European Neuropsychopharmacology.

[202]  F. Frankenburg,et al.  Clozapine and body mass change , 1998, Biological Psychiatry.

[203]  D. Greenblatt,et al.  Potassium, antipsychotic agents, arrhythmias, and sudden death. , 1998, Journal of clinical psychopharmacology.

[204]  M. Berk,et al.  Risperidone compared to haloperidol in cannabis-induced psychotic disorder: A double blind randomized controlled trial. , 2000 .

[205]  H. Helmchen.  Clinical experience with clozapine in Germany , 2004, Psychopharmacology.

[206]  M. Jann,et al.  Economic Considerations and Formulary Management of Oral Antipsychotics , 1998 .

[207]  M. Weller,et al.  Clozapine-induced neuroleptic malignant syndrome: another inconclusive case report. , 1996, Australian and New Zealand journal of medicine.

[208]  G. Oster,et al.  The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. , 1999, The Journal of clinical psychiatry.

[209]  T. Sharma,et al.  171. Information processing deficits in schizophrenia: effects of risperidone as compared to typical antipsychotics , 2000, Biological Psychiatry.

[210]  M. Serrano-Dueñas.  Atypical antipsychotics: Clozapine‐related cardiac complications , 2000, Movement disorders : official journal of the Movement Disorder Society.

[211]  M. Snaterse,et al.  A Retrospective, Naturalistic Review Comparing Clinical Outcomes of In-Hospital Treatment with Risperidone and Olanzapine , 2000 .

[212]  F. Frankenburg,et al.  Bladder dysfunction associated with clozapine therapy. , 1996, The Journal of clinical psychiatry.

[213]  F. Frankenburg,et al.  Fever associated with clozapine administration. , 1995, The American journal of psychiatry.

[214]  W. Fleischhacker,et al.  Adverse effects of antipsychotic drugs , 1995, International clinical psychopharmacology.

[215]  H. Bürki.  Extrapyramidal side-effects. , 1979, Pharmacology & therapeutics. Part B: General & systematic pharmacology.

[216]  B. V. Zwieten-Boot,et al.  Placebo-controlled trials in schizophrenia , 1998, European Neuropsychopharmacology.

[217]  W. Fleischhacker,et al.  Transient neutropenia induced by clozapine. , 1992, Psychopharmacology bulletin.

[218]  M. Olkinuora,et al.  CLOZAPINE AND AGRANULOCYTOSIS , 1975, The Lancet.

[219]  S. Lankappa,et al.  Quetiapine for schizophrenia. , 2004, The Cochrane database of systematic reviews.

[220]  W. Fleischhacker,et al.  Adverse effects of antipsychotic drugs , 1994 .

[221]  M. Kotler,et al.  Abnormal heart rate variability in clozapine treated patients , 1999, European Neuropsychopharmacology.

[222]  D. Benedek,et al.  Pharmacologic treatment of patients hospitalized with the diagnosis of schizoaffective disorder. , 2001, The Journal of clinical psychiatry.

[223]  Dan J Stein,et al.  The new-generation antipsychotics - integrating the neuropathology and pharmacology of schizophrenia , 1999 .

[224]  R. Chatterton.  Eosinophilia after Commencement of Clozapine Treatment , 1997, The Australian and New Zealand journal of psychiatry.

[225]  B. Kinon,et al.  Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[226]  Möller Hj.  Amisulpride: a review of its efficacy in schizophrenia. , 2000 .

[227]  S. Schulz,et al.  Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. , 1996, Journal of child and adolescent psychopharmacology.

[228]  A. Mackellar,et al.  Efficacy of ‘seroquel’ for the treatment of negative symptoms is comparable with that of olanzapine and risperidone , 2000, Schizophrenia Research.

[229]  S. Kuha,et al.  Long-term effect of clozapine in schizophrenia a retrospective study of 108 chronic schizophrenics treated with clozapine for up to 7 years , 1986 .

[230]  J. Penn,et al.  Weight gain associated with risperidone. , 1996, Journal of clinical psychopharmacology.

[231]  Z. Cernovsky,et al.  Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life , 2000, Schizophrenia Research.

[232]  J. Camm,et al.  Risk of torsades de pointes with non-cardiac drugs , 2000, BMJ : British Medical Journal.

[233]  Christopher S. Thomas,et al.  The use of clozapine , 1995 .

[234]  H. Meltzer,et al.  Substance abuse and clozapine treatment. , 1994, The Journal of clinical psychiatry.

[235]  H. Meltzer,et al.  Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. , 1994, The American journal of psychiatry.

[236]  D. Owens.  The spectrum of depressive phenomena after spousal bereavement. , 1994 .

[237]  J. Sweeney,et al.  Adverse Effects of Risperidone on Eye Movement Activity: A Comparison of Risperidone and Haloperidol in Antipsychotic-Naive Schizophrenic Patients , 1997, Neuropsychopharmacology.

[238]  M. Srisurapanont,et al.  Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials. , 1999, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[239]  N. Keks,et al.  Risperidone (Risperdal): clinical experience with a new antipsychosis drug. , 1999, Expert opinion on investigational drugs.

[240]  R. Buchanan,et al.  Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. , 1999, The American journal of psychiatry.

[241]  P. Peterson,et al.  Clozapine therapy in a state hospital: Patient care and policy implications , 1996, Administration and Policy in Mental Health and Mental Health Services Research.

[242]  S. Kapur,et al.  Pharmacotherapy of first-episode schizophrenia , 1998, British Journal of Psychiatry.

[243]  K. Goa,et al.  Risperidone. A pharmacoeconomic review of its use in schizophrenia. , 1998, PharmacoEconomics.

[244]  E. Leinonen,et al.  Clozapine decreases the level of anxiety and aggressive behaviour in patients with therapy- refractory schizophrenia , 1994 .

[245]  H. Kraemer,et al.  Clinical Outcome in a Randomized 1-Year Trial of Clozapine Versus Treatment as Usual for Patients With Treatment-Resistant Illness and a History of Mania , 1999 .

[246]  J. Lieberman,et al.  Clinical implications of clozapine discontinuation: report of an NIMH workshop. , 1995, Schizophrenia bulletin.

[247]  M. Krebs,et al.  Tardive dystonia induced by risperidone. , 1999, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[248]  R. Shelton,et al.  Olanzapine plus fluoxetine: Double-blind and open-label results in treatment-resistant major depressive disorder , 1999, European Neuropsychopharmacology.

[249]  P. Masand,et al.  Switching Antipsychotic Therapies , 2000, The Annals of pharmacotherapy.

[250]  K. Dickersin,et al.  Systematic Reviews: Identifying relevant studies for systematic reviews , 1994 .

[251]  W. Sitarz.  Comment: Delayed Risperidone-Induced Neuroleptic Malignant Syndrome , 1996, The Annals of pharmacotherapy.

[252]  J. Stevens.  Clozapine: The Yin and Yang of seizures and psychosis , 1995, Biological Psychiatry.

[253]  R. Blashfield,et al.  Psychotropic medication and priapism: a comprehensive review. , 1990, The Journal of clinical psychiatry.

[254]  J. O'hanlon,et al.  Extrapyramidal side effects and negative symptoms after subchronic use of modern and classical antipsychotic drugs with healthy volunteers , 2000, Schizophrenia Research.

[255]  E. Edgell,et al.  Resource use and quality of life of olanzapine compared with risperidone; Results from an international randomized clinical trial , 1998, European Neuropsychopharmacology.

[256]  V. Tapson.  Risk of venous thromboembolism with use of antipsychotic drugs , 2000, The Lancet.

[257]  W. Jungi,et al.  [Frequent cases of agranulocytosis due to clozapin (leponex) in eastern Switzerland]. , 1977, Schweizerische medizinische Wochenschrift.

[258]  J. Markowitz,et al.  New onset diabetes and atypical antipsychotics , 2001, European Neuropsychopharmacology.

[259]  L. Ereshefsky,et al.  Neuroleptic Malignant Syndrome Associated With Clozapine Monotherapy , 1993, Pharmacotherapy.

[260]  M. Tohen,et al.  Long-term olanzapine treatment: Efficacy and safety in manic patients with and without psychotic features , 1999, European Neuropsychopharmacology.

[261]  S. Gupta,et al.  Risperidone: a once-daily dosage schedule. , 1995, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[262]  M. Toprac,et al.  Savings in hospital bed-days related to treatment with clozapine. , 1994, Hospital & community psychiatry.

[263]  G. Gardos,et al.  The Evaluation and Treatment of Neuroleptic‐Induced Movement Disorders , 1995, Harvard review of psychiatry.

[264]  K. Reeves,et al.  Intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation , 1998, European Psychiatry.

[265]  N. Kaplowitz,et al.  Hepatotoxicity of psychotropic drugs , 1999, Hepatology.

[266]  Candace S. Brown,et al.  Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy , 1999, The Annals of pharmacotherapy.

[267]  J. Rybakowski,et al.  The effect of treatment with risperidone vs phenothiazine neuroieptics on eye tracking of schizophrenic patients during two fixation tasks , 1998, European Neuropsychopharmacology.

[268]  M. Maj,et al.  Clozapine plasma levels and time to clinical response in a standardized trial , 2000, European Neuropsychopharmacology.

[269]  M. Ackenheil,et al.  Clozapine — pharmacokinetic investigations and biochemical effects in man , 2004, Psychopharmacology.

[270]  P. Chue,et al.  Antipsychotic agents and QT changes. , 2000, Journal of psychiatry & neuroscience : JPN.

[271]  K. Reeves,et al.  A randomized, double-blind comparison of rapid-acting, intramuscular ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation , 1998, European Neuropsychopharmacology.

[272]  C. Spencer,et al.  Quetiapine : A Review of its Use in Schizophrenia. , 1998, CNS drugs.

[273]  B. Mulsant,et al.  Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. , 1995, Psychopharmacology bulletin.

[274]  S. Pallanti,et al.  Cognitive subjective disturbances of schizophrenia: Effect of atypical neuroleptics , 1999, European Neuropsychopharmacology.

[275]  J. Lönnqvist,et al.  Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. , 1999, The Journal of clinical psychiatry.

[276]  M. Weller,et al.  Clozapine and neuroleptic malignant syndrome: a never-ending story. , 1997, Journal of clinical psychopharmacology.

[277]  D. Naber,et al.  Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients , 2004, Psychopharmacology.

[278]  J. Rabinowitz,et al.  Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. , 2001, The American journal of psychiatry.

[279]  U. Trenckmann.  Risperidone Olanzapin Drug Outcomes study in Schizophrenia (RODOS) — first results of the German data , 1999, European Neuropsychopharmacology.

[280]  E. Rüther,et al.  [The incidence of abnormal EEG patterns with clozapine therapy (author's transl)]. , 1978, Arzneimittel-Forschung.

[281]  J. Sievering,et al.  [Retrospective study of drug-induced agranulocytosis in hospitalized patients in Geneva and comparison with cases reported to IOCM]. , 1998, Swiss medical weekly.

[282]  N. Sandler,et al.  Quetiapine and risperidone in outpatients with psychotic disorders: Results of the QUEST trial , 1999, European Neuropsychopharmacology.

[283]  B. Martin,et al.  Expenditures for treating schizophrenia: a population-based study of Georgia Medicaid recipients. , 1998, Schizophrenia bulletin.

[284]  Toshihito Suzuki,et al.  Convulsive Seizures in Schizophrenic Patients Induced by Zotepine Administration , 1992, The Japanese journal of psychiatry and neurology.

[285]  A. Hale.  A review of the safety and tolerability of sertindole , 1998, International clinical psychopharmacology.

[286]  David Taylor,et al.  Tolerability of Atypical Antipsychotics , 2000, Drug safety.

[287]  C. Beasley,et al.  Relapse prevention with olanzapine , 2000, Schizophrenia Research.

[288]  J. Shuster.  Anaphylaxis Seen with a Special Dye; •Cholestasis Caused by Cetirizine; •Acarbose and Lymphocytic Colitis; •Seizures Caused by Intravenous Alatrofloxacin; •Pedal Edema Caused by Olanzapine; •Disturbances in Electrolyte Homeostasis as an Adverse Effect of Gentamicin Therapy , 2000 .

[289]  T. Wetterling,et al.  [Body weight increase: a side effect of zotepin (Nipolept)?]. , 1996, Der Nervenarzt.

[290]  W. Reid,et al.  Psychotropic medications and glaucoma , 1980 .

[291]  Z. Dernovsek,et al.  Risperidone-induced leucopenia and neutropenia , 1997, British Journal of Psychiatry.

[292]  P. Weiden,et al.  Atypical antipsychotic drugs and long-term outcome in schizophrenia. , 1996, The Journal of clinical psychiatry.

[293]  D. Gardner,et al.  Drug and resource use evaluation of risperidone and olanzapine in inpatients with outpatient follow-up , 1999, European Neuropsychopharmacology.

[294]  L. Sher,et al.  White-blood-cell monitoring and clozapine , 1995, The Lancet.

[295]  D. Jeste,et al.  A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial , 1997, Psychopharmacology.

[296]  S. Potkin,et al.  Switching from risperidone to ziprasidone: An interim analysis of a 6-week study , 1999, European Neuropsychopharmacology.

[297]  S. Strakowski,et al.  The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. , 2000, The Journal of clinical psychiatry.

[298]  S. Hirsch,et al.  Pitfalls and Problems of the Long Term Use of Neuroleptic Drugs in Schizophrenia , 1993, Drug safety.

[299]  W. Reid,et al.  Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. , 1998, The Journal of clinical psychiatry.

[300]  J. Libiger,et al.  Clozapine in the treatment of schizophrenic patients: an international multicenter trial. , 1987, Clinical therapeutics.

[301]  P. Krupp,et al.  Leponex — associated granulocytopenia: a review of the situation , 2004, Psychopharmacology.

[302]  C D Naylor,et al.  Meta-analysis and the meta-epidemiology of clinical research , 1997, BMJ.

[303]  C. Clark,et al.  Effects of clozapine for non-treatment-resistant patients with schizophrenia. , 1999, Psychiatric services.

[304]  J. Tweed,et al.  Efficacy of zotepine in schizophrenia — A global meta-analysis , 1998, European Neuropsychopharmacology.

[305]  D. Langbehn,et al.  Increased risk of side-effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. , 2000, Pharmacopsychiatry.

[306]  R. Dittmann,et al.  Olanzapine treatment of psychotic adolescents — change of body weight and adverse event profile , 1999, European Neuropsychopharmacology.

[307]  C. Dalmady-Israel,et al.  Cardiomyopathy Associated with Clozapine , 1996, The Annals of pharmacotherapy.

[308]  R. Rosenheck,et al.  Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. , 2000, The Journal of clinical psychiatry.

[309]  A. Kirkegaard,et al.  An investigation of some side effects in 47 psychotic patients during treatment with clozapine and discontinuing of the treatment. , 1979, Arzneimittel-Forschung.

[310]  B. Kinon,et al.  Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. , 2000, The Journal of clinical psychiatry.

[311]  H. Meltzer,et al.  Path analysis of the Zeus study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable, schizophrenia , 2000, Schizophrenia Research.

[312]  U. Lepola,et al.  Neuroleptic malignant syndrome Five cases and a review , 1989 .

[313]  M. Edwardes,et al.  Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. , 2001, Clinical therapeutics.

[314]  Hoes Mj.  [Indications for, limitations, and hazards of neuroleptic agents]. , 1980 .

[315]  G. Gadeholt,et al.  [Treatment with neuroleptics]. , 1990, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[316]  Laporta Ld.  More on obsessive-compulsive symptoms and clozapine. , 1994 .

[317]  M. Lader.  Rating Scales in Schizophrenia , 2000 .

[318]  G. Remington,et al.  Clozapine: Current Status and Role in the Pharmacotherapy of Schizophrenia , 1996, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[319]  F. Maloisel,et al.  Drug-associated agranulocytosis: experience at Strasbourg Teaching Hospital. , 1999, Archives of internal medicine.

[320]  S. Leurgans,et al.  Olanzapine and clozapine , 2000, Neurology.

[321]  P. Morel,et al.  [Schizophrenia, affective symptoms and clozapine]. , 1995, L'Encephale.

[322]  M. Myrhed,et al.  [Clozapine--a new antipsychotic agent used in treatment resistance. A good effect but a great risk of adverse effects]. , 1989, Lakartidningen.

[323]  A. Kellam,et al.  The (Frequently) Neuroleptic (Potentially) Malignant Syndrome , 1990, British Journal of Psychiatry.

[324]  C. Salzman,et al.  Effects of psychotropic medications on pancreatic function: a review. , 1999, Harvard review of psychiatry.

[325]  J. Bobes,et al.  P02.320 Safety and effectiveness of olanzapine versus typical antipsychotic drugs in the treatment of inpatients with schizophrenia (Europa study) , 2000, European Psychiatry.

[326]  S. Kasper,et al.  Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance , 2000, International clinical psychopharmacology.

[327]  P. Gayral,et al.  [Leponex: experience of the hospital pharmacist]. , 1995, L'Encephale.

[328]  R. Lewis.  Typical and Atypical Antipsychotics in Adolescent Schizophrenia: Efficacy, Tolerability, and Differential Sensitivity to Extrapyramidal Symptoms , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[329]  W. Fleischhacker,et al.  Risk factors for the development of neuroleptic induced akathisia , 1997, European Neuropsychopharmacology.

[330]  P. Gaszner.  Clozapine treatment of different psychoses , 2000, European Neuropsychopharmacology.

[331]  W. Fleischhacker,et al.  Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. , 1999, The American journal of psychiatry.

[332]  Pradhan Sc.  Clozapine-induced urinary incontinence: facts or artefacts? , 2000 .

[333]  A. Breier,et al.  The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. , 2000, Clinical therapeutics.

[334]  Susan Gaile,et al.  SPEECH DISTURBANCE AND MARKED DECREASE IN FUNCTION SEEN IN SEVERAL OLDER PATIENTS ON OLANZAPINE , 1998, Journal of the American Geriatrics Society.

[335]  J. Werry.  HIGH‐DOSE OLANZAPINE IN AN ADOLESCENT , 1999 .

[336]  L. Fabre,et al.  Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. , 1999, The American journal of psychiatry.

[337]  C. Gaussarès.  [Indications for clozapine]. , 1996, L'Encephale.

[338]  A. Beckett,et al.  SIDE-EFFECTS OF DRUGS. , 1965, Lancet.

[339]  E. Rüther,et al.  Six years of drug surveillance in psychiatric inpatients , 1988 .

[340]  H. Möller.  Novel antipsychotics and negative symptoms , 1998, International clinical psychopharmacology.

[341]  W. Glazer,et al.  Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals. , 1999, Psychiatric services.

[342]  R. E. Hemphill,et al.  An investigation of clozapine in the treatment of acute and chronic schizophrenia and gross behaviour disorders. , 1975, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[343]  T. Brewerton,et al.  Delirium associated with clozapine and benzodiazepine combinations. , 1995, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[344]  P. Veys,et al.  Clinical Experience of Clozapine-Induced Neutropenia in the UK , 1992, Drug safety.

[345]  L. Perquin,et al.  What is the experience with sertindole in clinical practice , 1999 .

[346]  H. Meltzer,et al.  Reducing Suicide Risk in Schizophrenia , 2000 .

[347]  A. Maynard,et al.  Building castles on sands or quicksands? , 1998, British Journal of Psychiatry.

[348]  I. Fras,et al.  CLINICAL EXPERIENCE WITH REISPERIDONE , 1995 .

[349]  P. Martin.  [Medical economic impact of schizophrenia]. , 1995, L'Encephale.

[350]  Lu Mk.  [Clinical analysis in the main side effects of clozapine: enclosed 600 cases report]. , 1991 .

[351]  J. Lieberman,et al.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. , 1999, Schizophrenia bulletin.

[352]  J. Mackell,et al.  The impact of weight gain on quality of life among individuals with schizophrenia , 1999, European Neuropsychopharmacology.

[353]  P. Sienaert,et al.  Sexual dysfunction: The unspoken side effect of antipsychotics , 1998, European Psychiatry.

[354]  Abraham Weizman,et al.  Use of atypical neuroleptics in child and adolescent psychiatry. , 1998, The Journal of clinical psychiatry.

[355]  K. Ice,et al.  A 3-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania , 2000, European Neuropsychopharmacology.

[356]  S. Leucht,et al.  Meta-analysis of amisulpride — A selective dopamine receptor antagonist with an “atypical” profile , 2000, European Neuropsychopharmacology.

[357]  K. Melkersson,et al.  Insulin and leptin levels in patients with schizophrenia or related psychoses – a comparison between different antipsychotic agents , 2001, Psychopharmacology.

[358]  M. Tohen,et al.  Switching between Clozapine and Risperidone Treatment , 1997, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[359]  DJ King.  Quetiapine: Results of four phase II and III clinical trials , 1998, European Psychiatry.

[360]  G. Tollefson,et al.  Olanzapine reduces psychotic symptoms and behavioral disturbances associated with alzheimer's disease , 2000, Schizophrenia Research.

[361]  J. M. Pierre,et al.  Nonextrapyramidal side effects of novel antipsychotics , 2000 .

[362]  K. Gillman.  Paradoxical pattern of haematological risk with clozapine. , 2000, The British journal of psychiatry : the journal of mental science.

[363]  D. Menkes.  Clozapine in the management of schizophrenia. Risperidone is less toxic but equally effective. , 1993, BMJ.

[364]  A. Green,et al.  Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. , 2000, Journal of clinical psychopharmacology.

[365]  A. Loonen,et al.  Comparison of indications and treatment outcomes of risperidone in elderly and younger patients , 2000, European Neuropsychopharmacology.

[366]  E. Stip,et al.  The Effect of Risperidone on Cognition in Patients with Schizophrenia , 1996, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[367]  G. Tollefson,et al.  P.2.015 Olanzapine versus haloperidol: Analysis of schizophrenic patients from the multi-center international trial , 1997, European Neuropsychopharmacology.

[368]  R. Tavcar,et al.  Antipsychotic drugs and risk of homicide , 2000, The Lancet.

[369]  P. Masand.  Relative weight gain among antipsychotics. , 1999, The Journal of clinical psychiatry.

[370]  G. Simpson,et al.  Double-blind study of clozapine dose response in chronic schizophrenia. , 1999, The American journal of psychiatry.

[371]  J. Shuster.  Synercid-Induced Myalgias; Another Allergic Reaction to Methylprednisolone; More on Heparin Flush–Induced Thrombocytopenia; Hiccups and Steroid Injections; Topical Tricyclic Toxicity?; Priapism with OTC Hormonal Agent; Quinine-induced Thrombocytopenia and Neutropenia; Hyperventilation and Quetiapine , 2000 .

[372]  R. Dickson,et al.  Economics of Schizophrenia , 1995, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[373]  H. Munitz,et al.  The effect of olanzapine on the psychopathologic clusters in patients refractory for clozapine treatment , 1999, European Neuropsychopharmacology.

[374]  J. Louwerens,et al.  Therapy resistance: The effectiveness of the second antipsychotic drug, a multicentric double-blind comparative study (‘switch study’) , 2000, Schizophrenia Research.

[375]  P. Buckley.  Novel Antipsychotics and Patient Care in State Hospitals , 1998, The Annals of pharmacotherapy.

[376]  S. Potkin,et al.  Benefits of ziprasidone in stable outpatient schizophrenics switched from conventional antipsychotics, olanzapine, or risperidone , 2000, European Neuropsychopharmacology.

[377]  J. Kaprio,et al.  Life satisfaction and suicide: a 20-year follow-up study. , 2001, The American journal of psychiatry.

[378]  S. Otsuki,et al.  Antimanic effect of zotepine. , 1986, Clinical therapeutics.

[379]  M. Tohen,et al.  Olanzapine: Acute and long-term efficacy in bipolar I patients , 2000, Schizophrenia Research.

[380]  S. Kumra,et al.  RISPERIDONE-INDUCED HEPATOTOXICITY? , 1998 .

[381]  D. Luchins,et al.  Pharmacoeconomic Studies of Atypical Antipsychotics: Review and Perspective , 1998 .

[382]  R. Fireworker,et al.  Clozapine reduces rehospitalization among schizophrenia patients. , 1998, Psychopharmacology bulletin.

[383]  E. Haller,et al.  Clozapine--a new and different neuroleptic. , 1990, The Western journal of medicine.

[384]  N. Chan.  Clozapine and sudden death , 2000, The Lancet.

[385]  R. Kahn,et al.  Perception, mental imagery and reality discrimination in hallucinating and non-hallucinating schizophrenic patients. , 2000, The British journal of clinical psychology.

[386]  E. Wiebe.  Weight Gain with Clozapine Treatment , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[387]  J. Rapoport,et al.  Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[388]  J. Lieberman,et al.  Adverse effects of psychotropic drugs , 1992 .

[389]  E. Dunayevich,et al.  Risperidone and clozapine for treatment-resistant schizophrenia. , 1999, The American journal of psychiatry.

[390]  P. Malek-Ahmadi.  Re: Cytokines and Agranulocytosis Induced by Clozapine , 1996, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[391]  B. Jones,et al.  The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. , 2001, The Journal of clinical psychiatry.

[392]  C. Tamminga.  The Promise of New Drugs for Schizophrenia Treatment , 1997, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[393]  E. Rüther,et al.  Efficacy of risperidone on affective symptoms in acute schizophrenia , 1999, European Neuropsychopharmacology.

[394]  D. Meltzer.  Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia. , 1999, The Journal of clinical psychiatry.

[395]  Deanna M. Guith.  Clozapine: Serious Adverse Side Effects, Drug Interactions, and Other Complications of Therapy , 1996 .

[396]  E. Eşel,et al.  Improvement of tardive dyskinesia in a bipolar patient with olanzapine , 2000, European Psychiatry.

[397]  C. Barbui,et al.  Clinical trials of new antipsychotics: a critical appraisal. , 1999, International clinical psychopharmacology.

[398]  Candace S. Brown,et al.  Atypical Antipsychotics: Part II Adverse Effects, Drug Interactions, and Costs , 1999, The Annals of pharmacotherapy.

[399]  M. van Dijk,et al.  A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[400]  R. Cookson,et al.  The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited. , 1999, International journal of psychiatry in clinical practice.

[401]  M. Krebs.  [Current data on neurologic sequelae caused by neuroleptics]. , 1995, L'Encephale.

[402]  J. Chiles,et al.  Weight gain associated with clozapine. , 1990, The American journal of psychiatry.

[403]  R. Williams.  Optimal dosing with risperidone: updated recommendations. , 2001, The Journal of clinical psychiatry.

[404]  A. Vesterby,et al.  [Sudden death during treatment with clozapine (Leponex)]. , 1980, Ugeskrift for laeger.

[405]  P. Pillans.  National Centre for Adverse Reactions Monitoring report for the period 1 July, 1994 to 3 June, 1996. , 1997, The New Zealand medical journal.

[406]  W. Glazer,et al.  Expected incidence of tardive dyskinesia associated with atypical antipsychotics. , 2000, The Journal of clinical psychiatry.

[407]  J. Connelly,et al.  Experience With Clozapine in a Community Mental Health Care Setting , 1998, Southern medical journal.

[408]  Abraham Weizman,et al.  Diminished Suicidal and Aggressive Behavior, High Plasma Norepinephrine Levels, and Serum Triglyceride Levels in Chronic Neuroleptic‐Resistant Schizophrenic Patients Maintained on Clozapine , 1998, Clinical neuropharmacology.

[409]  B. Kinon.  The routine use of atypical antipsychotic agents: maintenance treatment. , 1998, The Journal of clinical psychiatry.

[410]  H. Echizen,et al.  Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions , 1999, European Journal of Clinical Pharmacology.

[411]  A. M. Fuchs.  Clozaril—Saving lives , 1994, Biological Psychiatry.

[412]  O. Spigset,et al.  Hyponatremia during treatment with clomipramine, perphenazine, or clozapine: study of therapeutic drug monitoring samples. , 1996, Journal of clinical psychopharmacology.

[413]  T. McGlashan.  A selective review of recent North American long-term followup studies of schizophrenia. , 1988, Schizophrenia bulletin.

[414]  J. Lieberman,et al.  Clozapine pharmacology and tardive dyskinesia , 2004, Psychopharmacology.

[415]  S. Woods.  Olanzapine and tardive dyskinesia , 1999, British Journal of Psychiatry.

[416]  J. Kane.  Sertindole: a review of clinical efficacy , 1998, International clinical psychopharmacology.

[417]  W. Honer,et al.  Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone , 1996, Biological Psychiatry.

[418]  L. Offerhaus.  [Foreign report on side effects of drugs]. , 1991, Nederlands tijdschrift voor geneeskunde.

[419]  A. Vagnucci,et al.  Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone , 2001, Schizophrenia Research.

[420]  H. Lamb,et al.  Erratum to: Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia , 1998 .

[421]  J. Tweed,et al.  A comparison of newer vs traditional antipsychotics and placebo using meta-analysis techniques , 1998, European Neuropsychopharmacology.

[422]  K. Gregor,et al.  Functional outcomes in schizophrenia: A European comparison of olanzapine and haloperidol , 2000, Schizophrenia Research.

[423]  M. Hert,et al.  A meta-analysis of efficacy and safety of risperidone and olanzapine , 2000, European Neuropsychopharmacology.

[424]  K. Meehan,et al.  Change in positive symptoms with olanzapine compared to other antipsychotic agents , 1999, European Neuropsychopharmacology.

[425]  A. Breier,et al.  The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome , 1999, Biological Psychiatry.

[426]  W. Maier,et al.  Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial , 2000 .

[427]  J. Adams,et al.  Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. , 1996, Psychopharmacology bulletin.

[428]  D. Taylor,et al.  Atypical antipsychotics and hyperglycaemia , 2001, International clinical psychopharmacology.

[429]  L. Cohen,et al.  Suicide and schizophrenia: data from a prospective community treatment study. , 1990, The American journal of psychiatry.

[430]  A. Awad,et al.  Quality of Life and New Antipsychotics in Schizophrenia Are Patients Better Off? , 1999, The International journal of social psychiatry.

[431]  M. Tohen,et al.  Is olanzapine a mood-stabilizer? , 2000, Schizophrenia Research.

[432]  B. A. Cardwell,et al.  Seizure activity in combined clozapine and ECT: a retrospective view. , 1995, Convulsive therapy.

[433]  D. Daniel,et al.  Intramuscular (IM) ziprasidone: A novel treatment for the short-term management of agitated psychotic patients , 2000, Schizophrenia Research.

[434]  M. Lader.  Some adverse effects of antipsychotics: prevention and treatment. , 1999, The Journal of clinical psychiatry.

[435]  J. Kane,et al.  Medical complications of new antipsychotic drugs. , 1996, Schizophrenia bulletin.

[436]  S. Woods,et al.  Consistency of atypical antipsychotic superiority to placebo in recent clinical trials , 2001, Biological Psychiatry.

[437]  R. Kerwin.  Adverse reaction reporting and new antipsychotics , 1993, The Lancet.

[438]  B. Lund,et al.  Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial , 2001, Journal of clinical psychopharmacology.

[439]  A. Green,et al.  Clozapine: benefits and risks. , 1990, Hospital & community psychiatry.

[440]  G. Remington,et al.  Clozapine augmentation: safety and efficacy. , 2000, Schizophrenia bulletin.

[441]  N. Keks.  Impact of newer antipsychotics on outcomes in schizophrenia. , 1997, Clinical therapeutics.

[442]  L. Kopala,et al.  Spontaneous and drug‐induced movement disorders in schizophrenia , 1996, Acta psychiatrica Scandinavica. Supplementum.

[443]  B. Lawrence,et al.  Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. , 1998, Psychopharmacology bulletin.

[444]  D. Revicki.  Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia , 1999, Schizophrenia Research.

[445]  D. Luchins,et al.  Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. , 1998, Psychiatric services.

[446]  D. Goff.  Have the Serotonin‐Dopamine Antagonists Rendered Traditional Antipsychotic Agents Obsolete? , 1995, Harvard review of psychiatry.

[447]  G. Meterissian,et al.  Risperidone-Induced Neuroleptic Malignant Syndrome: A Case Report and Review , 1996, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[448]  H. Hinterhuber,et al.  Tardive Dyskinesia Prevalence Rates During a Ten‐Year Follow‐Up , 1995, The Journal of nervous and mental disease.

[449]  K. Meehan,et al.  Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents , 1999, European Neuropsychopharmacology.

[450]  R. Leadbetter,et al.  Clozapine-induced weight gain. , 1990, The American journal of psychiatry.

[451]  G. Hayes,et al.  Clozapine-induced constipation. , 1995, The American journal of psychiatry.

[452]  J. Rapoport,et al.  Antipsychotics in children and adolescents. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[453]  I. Wojdyslawska,et al.  [Clinical evaluation of clozapine. A follow-up study]. , 1976, Psychiatria polska.